Imunon, Inc. Long-Term Debt, Maturity, Remainder of Fiscal Year
Imunon, Inc. (IMNN) had Long-Term Debt, Maturity, Remainder of Fiscal Year of $1.50 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Notes › Commitment and Contingencies
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear · last filed 2023-05-11
- 2023-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $1.50M.
- 2020-03-31: Long-Term Debt, Maturity, Remainder of Fiscal Year $2.50M.
| Period end | Long-Term Debt, Maturity, Remainder of Fiscal Year |
|---|---|
| 2023-03-31 | $1.50M 10-Q · filed 2023-05-11 |
| 2020-03-31 | $2.50M 10-Q · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |